Skip to content

Non-antibiotic therapy in children with chronic abdominal pain and Helicobacter pylori infection: a randomized clinical controlled trial

Non-antibiotic therapy in children with chronic abdominal pain and Helicobacter pylori infection: a randomized clinical controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062024
Enrollment
Unknown
Registered
2022-07-19
Start date
2022-07-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic abdominal pain and Helicobacter pylori infection in children

Interventions

Routine antibiotic treatment group:antibiotic
group 1 of non-antibiotic therapy:Clostridium Butyricum Powder,Live+ Lamb's Tripe Extract and Vitamin B12 Granules
group 2 of non-antibiotic therapy:Bacillus coagulans Tablets,Live + Lamb's Tripe Extract and Vitamin B12 Granules
group 3 of non-antibiotic therapy:Clostridium Butyricum Powder,Live+Bacillus coagulans Tablets,Live + Lamb's Tripe Extract and Vitamin B12 Granules

Sponsors

Shanxi Bethune Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Rome III diagnostic criteria of functional gastrointestinal disease, abdominal pain occurs at least once a week and lasts for 2 months, and there is no organic disease. 2. Aged between 7-12 years old; 3. Helicobacter pylori infection was confirmed by C13 breath test; 4. Patients voluntarily receive non antibiotic therapy; 5. Not taking antibiotics within one month; 6. Never received Helicobacter pylori eradication treatment before.

Exclusion criteria

Exclusion criteria: 1. Children with mental diseases or mental disorders have unclear consciousness or do not have normal cognitive ability; 2. Those who cannot strictly follow the doctor's advice, resulting in invalid results; 3. Children who have a history of allergy to microecological agents in the past; 4. There are serious heart, liver and kidney diseases; 5. Other researchers believe that they are not suitable for selection; 6. No other microbial agents have been taken in the past month.

Design outcomes

Secondary

MeasureTime frame
Helicobacter pylori eradication rate;correlation between chronic abdominal pain and Helicobacter pylori;incidence of adverse reactions;

Primary

MeasureTime frame
effective rate of chronic abdominal pain;

Countries

China

Contacts

Public ContactWeihong Chen

Shanxi Bethune Hospital

whhchen@126.com13700500659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026